Kelly Bilodeau from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing		Ozempic for liver disease? Weight loss drugs could have even more to offer - 9 months ago Behind the breakthrough cancer therapy that just won a historic FDA nod - 9 months ago Kite’s next-gen CAR-T aims include quicker production and more disease targets - 9 months ago A new (old) mind-opening tool in the fight against Alzheimer’s disease - 10 months ago Pharma has a misinformation problem — and execs could be on the hook - 10 months ago Vaxxinity is brewing up meds for a spacefaring future - 10 months ago Tonix closes in on the first new fibromyalgia drug in more than a decade - 10 months ago Breast cancer tops list of most studied diseases - 10 months ago Controversial challenge trials offer unparalleled innovation — with ethical bumps - 10 months ago Pharma takes a gut check of microbiome drugs - 10 months ago Believe the hype? Mixed signals from AI’s impact on drug development - 11 months ago Alzheimer’s research is hot, but successful patient recruitment will determine its future - 11 months ago What are pharma’s next blockbusters? - 11 months ago Babson gets one step closer to delivering on Theranos-like blood testing - 11 months ago What’s being done to prepare for the next pandemic? - 12 months ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - 12 months ago The digital therapeutics revolution is here. Will payers play ball? - 12 months ago The weight loss market looks unstoppable. How high could it go? - 12 months ago Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help - 12 months ago As alcohol-related deaths climb, new drugs could curb the urge to drink - 12 months ago Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs - about 1 year ago Can Sarepta’s Duchenne gene therapy still deliver on its promise? - about 1 year ago Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline. - about 1 year ago An at-home flu vaccine? If approved, it could open the door to more DIY options - about 1 year ago Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls - about 1 year ago What’s next for COVID dark horse Novavax? - about 1 year ago Patient groups have become a powerhouse in R&D. Here’s a look at their impact. - about 1 year ago An ‘inverse vaccine’ takes aim at autoimmune diseases - about 1 year ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - about 1 year ago Has the science of anti-aging caught up with the dream of a longer life? - about 1 year ago The ALS therapy keeping the human pig heart transplant pumping - about 1 year ago Elderly exclusion: Clinical trials still fall short enrolling older adults - about 1 year ago Endangered horseshoe crabs could lead the charge in pharma’s animal-free future - about 1 year ago